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vivors, speciﬁ cally female survivors over 65 years had greater risk of work loss than 
general population. These ﬁ ndings should help working people concerned about 
employment after lung cancer. 
CANCER – Health-Care Use and Policy Studies
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OBJECTIVES: To assess the outpatient direct costs related to early and metastatic 
breast cancer (BC) management in Campania, a Southern Italy region. METHODS: 
This is a retrospective cohort study based on clinical records from 457 general prac-
titioners who managed an average of 630,000 inhabitants in Campania. Incident early 
BC cases from 2005 to 2007 were identiﬁ ed and costs related to outpatients manage-
ment were calculated until evidence of local recurrence or metastases (BC Event), 
death, revocation or the end of the database (December 31, 2009). For those patients 
who developed a BC event, costs for their disease management were further analyzed 
from the time of the event until death, revocation, or the end of the database. Monthly 
cost per patient was expressed in Euros. RESULTS: A total of 1529 patients with 
early BC were identiﬁ ed in the database. Of these, 112 women developed a BC event 
during the study period. At a median follow-up of 34 months, adjusted monthly 
primary care cost per patient was c151.87 in the subset of women with early BC. For 
those who experienced a BC event, at 24 months of follow-up, adjusted monthly 
primary care cost per patient was almost doubled: c289.15 (P < 0.0001). Main causes 
for this cost difference were related to increased number of specialists’visits, diagnostic 
procedures, and laboratory test once a BC event developed. CONCLUSIONS: Out-
patient’s management in women with metastatic BC is twice more expansive compared 
to management of women with early BC. Reasons for this increase are mainly due to 
increased frequency of imaging and diagnostic procedures in the metastatic BC subset. 
However, our study underestimates the total costs for metastatic BC patients’ manage-
ment because hospitalization and chemoptherapy costs are not included in our analy-
ses. Based on our data, secondary and tertiary prevention strategies must be signiﬁ cantly 
implemented in order to rationalize resource allocation.
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OBJECTIVES: Cancer patients from lower-income countries such as India often have 
limited access to modern medicines because of high costs. Using multiples of India’s 
per capita GDP as the threshold for economic value as suggested by the World Health 
Organization (WHO), decision analysis modeling was used to estimate a monthly cost 
for a hypothetical new cancer drug that provides a 3-month survival beneﬁ t to patients 
with metastatic colorectal cancer (mCRC). METHODS: A decision model was devel-
oped to simulate progression-free and overall survival in mCRC patients receiving 
chemotherapy ± the new drug. Outcomes for cancer control and side effects were 
obtained from randomized trials evaluating 1st and 2nd line chemotherapy in mCRC. 
Costs for chemotherapy were obtained from both public and private hospitals in India. 
Utility estimates measured as quality-adjusted life-years (QALY) were determined 
from 24 oncology nurses using the Time Trade-Off technique. These data were then 
used to estimate the monthly cost of the new drug using a threshold of $9300 per 
QALY gained, which is three times the Indian per capita GDP, as recommended by 
the WHO. RESULTS: The base-case analysis suggested that a monthly cost of $U.S.98 
would be considered cost-effective from the Indian public health-care perspective. If 
the drug were able to improve patient quality of life above the standard of care or 
survival from 3 to 6 months, the monthly drug cost could increase to $U.S.170 and 
$U.S.253 and offer the same value. CONCLUSIONS: The use of the WHO criteria 
for estimating a country-speciﬁ c drug price based on economic value for a developing 
country is feasible. However, the challenge would be to identify an appropriate 
threshold that would provide a balance between what patients/governments can afford 
to pay and the commercial viability of the product in the reference country.
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OBJECTIVES: Increasing the level of transparency of decision-making process of 
reimbursement for drugs used in oncology by facilitating online access to public 
information and other information regarding the refund of cancer drugs in Poland 
compared to solutions used in the world. METHODS: The project will develop a 
comprehensive system to monitor the transparency of reimbursement decision-making 
process in Poland consisting of: Guidelines and Clinical and Reimbursement Recom-
mendations Database (WiRKliR database) whose purpose is to collect documents from 
the Polish and selected countries of the clinical guidelines, registration, and decisions 
about the recommendations and decisions regarding reimbursement for cancer drugs 
and present information contained in them in a comprehensible and transparent. 
Reimbursement monitoring which aims to carry out continuous monitoring of the 
implementation of law and regulation in the ﬁ eld of oncology drug reimbursement 
and the acquisition of complementary information about the cancer drugs in the 
database WiRKliR. Reimbursement reports whose purpose is to discuss the issue of 
transparency of reimbursement through the analysis of procedures drawn up and 
applied by public authorities in dealing with citizens, with special emphasis on patients 
and pharmaceutical companies in the reimbursement decision-making process and to 
present the results of the various stages of our work. RESULTS: The most important 
results of the project include: increased transparency of institutions involved in the 
drug reimbursement decision-making process, the democratization of medical infor-
mation, provide decision-makers Polish health-care system expertise, to increase 
patient awareness about their rights and proposals for corrective actions (conclusions 
and recommendations) for public administration in the area of the refund. CONCLU-
SIONS: A comprehensive monitoring system for civil funding allocation process in the 
health-care system to counteract the imbalance of information.
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OBJECTIVES: A number of systemic therapies are available for the treatment of 
metastatic breast cancer (MBC)—including hormonal therapies, chemotherapeutic 
agents, and biologics—but long-term prognosis remains poor. There is a need for new 
treatments that improve survival and are effective in a greater proportion of patients. 
This research evaluates the recent clinical trial activity directed toward the treatment 
of MBC. METHODS: MBC trials were identiﬁ ed through a systematic search of the 
records within http://www.clinicaltrials.gov, using the search term “metastatic breast 
cancer OR stage IV breast cancer OR advanced breast cancer.” Trials with a start 
date from January 2008 onward were included and categorized by nature of interven-
tion (new investigational agent, drug launched for indications other than breast cancer, 
or approved breast cancer product); all trials that did not include a pharmaceutical 
(biological or drug) were for an unsuitable indication, or that were suspended, termi-
nated, or withdrawn were excluded. The remaining trials were evaluated for a number 
of variables, including phase of development and product type. The overall number 
of pharmaceuticals under investigation was also explored. RESULTS: The original 
search term identiﬁ ed 2014 trials, 365 of which met the inclusion criteria. a large 
proportion of these trials (41%) were evaluating products already approved for the 
treatment of breast cancer. Of the remaining trials, 68% were investigating new 
agents; the remainders were evaluating a product launched for an indication other 
than breast cancer. There were a total of 116 new products under investigation, 
although these were mainly at an early stage of development with just 8% of trials at 
Phase III/IV. CONCLUSIONS: MBC is a key area of research, with a large number 
of products in development. However, since the majority of clinical trials are at an 
early stage, it will be some years before these products impact patient treatment.
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OBJECTIVES: While there are several instances of products gaining expanded indica-
tions from secondary treatment to primary treatment/prevention, in some cases, 
expanded indications appear to buffer the drug utilization from competitors. However, 
the extent to which the later expanded indications impact the utilization of the product 
across the lifecycle, including following loss of exclusivity, is not well understood. The 
objective was to examine the prescribing volume of a drug throughout its lifecycle in 
conjunction with the uptake of a novel class of drugs launched for similar indications 
to examine the impact of the expanded primary treatment/prevention indications on 
competition. METHODS: Tamoxifen and the aromatase inhibitors letrozole and anas-
trozole were selected as case products. All three drugs are FDA indicated for the 
treatment of advanced breast cancer, yet tamoxifen is the only drug of the group FDA 
indicated for the primary prevention of breast cancer. From January 1992 to April 
2010, the volume of prescriptions (TRx) was collected monthly using SDI’s VONA 
database and grouped according to class sales by active molecule. RESULTS: Generic 
sales of tamoxifen maintained a high level after the 1998 approval for the primary 
prevention indication of “reduction in breast cancer incidence in high-risk women” 
despite competition within active breast cancer treatment indications from the aroma-
tase inhibitors. While the aromatase inhibitors launched in the mid-1990s, their uti-
lization did not begin to encroach on total tamoxifen prescriptions until the expiration 
of exclusivity for tamoxifen’s prevention indication in 2003. CONCLUSIONS: This 
preliminary analysis shows that the strategy of obtaining a later primary prevention 
indication may help maintain utilization of a compound across the lifecycle. The 
hypothesis that a prevention indication expansion could mitigate competition should 
be further examined among products where primary prevention and primary treatment 
indications have distinctly different dosages and/or branding and where the additional 
indication is protected by extended exclusivity.
